Navigation Links
Sigma(R) Launches Innovative ChIP Kit Technology For Epigenetic Research
Date:4/16/2008

Imprint(TM) ChIP Kit Offers a Complete Solution for the Study of

DNA-Protein Interactions

ST. LOUIS, April 16 /PRNewswire-FirstCall/ -- Sigma-Aldrich (Nasdaq: SIAL) today announced the launch of its Imprint(TM) Chromatin Immunoprecipitation Kit for epigenetic research (http://www.sigma.com/chip). The Imprint(TM) ChIP Kit provides a complete solution for Chromatin Immunoprecipitation, including columns and reagents for DNA purification as well as an integrated protocol for ChIP DNA amplification with the GenomePlex(R) Whole Genome Amplification Kit. This flexible format allows for immunoprecipitation and purification of DNA from mammalian cells or tissue in a convenient microwell format.

ChIP is an innovative technology that enables scientists to investigate complex DNA-protein interactions in vivo, potentially increasing the speed and accuracy of disease research and drug discovery. The Imprint(TM) ChIP Kit provides researchers with rapid and accurate results, enabling high-throughput, same-day downstream analyses via quantitative PCR, MS-PCR, and DNA sequencing as well as DNA microarray. With the shortest protocol time and highest throughput capabilities on the market, the Imprint(TM) ChIP Kit, offers significant time and cost savings to epigenetic researchers.

"Sigma's Imprint(TM) ChIP Kit incorporates all of the requirements for Chromatin Immunoprecipitation procedures," said Tim Fleming, Director of Global Commercial Marketing for Sigma-Aldrich Life Science. "These integrated tools will help researchers better understand complex protein networks and expedite epigenetic research and development."

The Imprint(TM) ChIP Kit complements Sigma Life Science's robust product line to support the epigenetic workflow, including the Imprint(TM) DNA Modification Kit as well as products for DNA purification, qPCR, sequencing and post-reaction clean-up. The Imprint(TM) ChIP Kit is based on Chromatin Immunoprecipitation (ChIP) technology licensed from Epigentek Group.

"This arrangement reinforces Epigentek's leading position in the epigenetic arena," said Adam Li, Chief Scientific Officer for Epigentek. "We share Sigma's commitment to developing the next generation of research tools for epigenetic research."

About Sigma-Aldrich: Sigma-Aldrich is a leading Life Science and High Technology company. Our biochemical and organic chemical products and kits are used in scientific and genomic research, biotechnology, pharmaceutical development, the diagnosis of disease and as key components in pharmaceutical and other high technology manufacturing. We have customers in life science companies, university and government institutions, hospitals, and in industry. Over one million scientists and technologists use our products. Sigma-Aldrich operates in 36 countries and has 7,900 employees providing excellent service worldwide. Sigma-Aldrich is committed to Accelerating Customer Success through Leadership in Life Science, High Technology and Service. For more information about Sigma-Aldrich, please visit our award-winning website at http://www.sigma-aldrich.com.

About Epigentek Group Inc: Epigentek Group Inc. is a biotechnology company that focuses on developing and providing innovative technology and products as a complete and systematic solution for epigenetics-related research and drug discovery. The company has developed a comprehensive portfolio of more than 400 proprietary products that are used all around the world by esteemed academia, leading pharmaceuticals, and cutting edge biotechnology companies. These unique products are specifically designed to make assays significantly more simple, fast, convenient and efficient than conventional methods. The company, particularly emphasizing speed and effectiveness in its technologies, continues to focus on epigenetic innovation and to extensively develop and enhance its product portfolio.

Cautionary Statement: This release contains forward-looking statements relating to future performance, goals, strategic actions and initiatives and similar intentions and beliefs and other statements regarding the Companies' expectations, goals, beliefs, intentions and the like, which involve assumptions regarding the Companies' operations and conditions in the markets the Companies serve. The Companies do not undertake any obligation to update these forward-looking statements.


'/>"/>
SOURCE Sigma-Aldrich
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Cypress Systems, Inc. Launches Cancer Prevention Health Campaign Using SelenoExcell(R)
2. Cellix Ltd. Launches VenaEC Biochip for Flow-based Cell-adhesion Assays
3. Schering-Plough Launches Productivity Transformation Program To Confront New Challenges
4. IC Sciences Launches ICS Alliance to Advance Development and Adoption of Informatics Instruments for Next Generation Healthcare
5. Biotage Launches New 24 Well Pyrosequencing(R) System
6. Ferring Initial Purchase Order and Guaranteed Letter of Credit Launches Five Year Contract
7. Encision Launches Next Generation of EnTouch(R) Handles for Advanced Laparoscopic Procedures
8. Sagent Pharmaceuticals Launches Cefazolin for Injection, USP
9. BioElectronics Launches 1 Day Breast Augmentation Recovery Kit
10. Allen Institute for Brain Science Launches Three New Landmark Atlas Projects Focusing on the Human Brain, Developing Brain and Spinal Cord
11. Altogen Biosystems Launches Custom Biotechnology Research Services: Generation of Stable Cell Lines and RNAi Cell Transfection Services
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... March 23, 2017 Kineta, Inc., a ... novel therapies in immuno-oncology, today announced the discovery ... molecule compounds that activate interferon response factor 3 ... demonstrate immune-mediated tumor regression in a murine colon ... who demonstrated complete tumor regression to initial drug ...
(Date:3/23/2017)... New York , March 23, 2017 ... blood plasma products and derivatives market is fragmented due to the presence ... players, such as Proliant, Thermo Fisher , and Sigma-Aldrich, compete ... leader, these three companies, collectively, held more than 76% of this ... ...
(Date:3/23/2017)... YORK , March 23, 2017 ... look at four equities in the Biotech industry: Sangamo ... Synthetic Biologics Inc. (NYSE MKT: SYN), and Regulus Therapeutics ... 21 st , 2017, Credit Suisse upgraded its rating on ... by downloading their free report at: ...
(Date:3/22/2017)... TARRYTOWN, N.Y. , March 22, 2017 Regeneron ... among the Regeneron Genetics Center (RGC), U.K. Biobank and GSK ... in the U.K. Biobank resource. The initiative will enable researchers ... of new medicines for a wide range of serious and ... ...
Breaking Biology Technology:
(Date:3/2/2017)... 2, 2017 Summary This report provides ... its partnering interests and activities since 2010. ... Read the full report: ... since 2010 report provides an in-depth insight into the partnering ... On demand company reports are prepared upon purchase ...
(Date:3/2/2017)... Australia , March 2, 2017 Australian ... Ltd (ASX: CYP), has signed an agreement with ... from the Monash Biomedicine Discovery Institute and Department of ... to conduct a further preclinical study to support the ... treatment of asthma.  Asthma is a ...
(Date:2/28/2017)... , February 28, 2017 News solutions for ... ... from 14 to 16 March, Materna will present ... show how seamless travel is a real benefit for passengers. ... biometrics to their passenger touch point solutions to take passengers through ...
Breaking Biology News(10 mins):